• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Controversial “right to try” bill fails in the House

March 14, 2018 By Sarah Faulkner

capitol hillA controversial bill that would grant terminal patients access to experimental therapies failed yesterday in the House. Although the “right to try” effort didn’t muster up enough votes to send it to the Senate, majority leader Rep. Kevin McCarthy (R-CA) said in a statement that the fight wasn’t over.

“We will try again, pass legislation, and bring hope to those whose only desire is the right to try to live,” he tweeted.

The House voted 259-140, falling short of the two-thirds majority needed to pass under the suspended rules.

Republicans argued that patients who are terminally ill deserve the chance to try unapproved therapies that could help keep them alive. But Democrats have pointed out that the effort could give false hope to patients and that circumventing the FDA could be dangerous.

Although there are fierce patient advocates lobbying on behalf of the right-to-try movement, there are also a number of patient advocacy groups arguing against the measure. Earlier this week, more than 75 organizations sent a letter to members of both parties in opposition of the bill.

Opponents of the bill have also noted that the FDA already has a program to give terminally-ill patients access to unapproved therapies – the compassionate use program.

Supporters of the bill counter by arguing that patients should be able to try any drug that could help them and that the bill, which requires a drug to have passed a Phase I trial, is safe.

The president threw his support behind the right-to-try movement earlier this year at his State of the Union speech.

“We also believe that patients with terminal conditions should have access to experimental treatments that could potentially save their lives,” Trump said, according to STAT. “People who are terminally ill should not have to go from country to country to seek a cure — I want to give them a chance right here at home. It is time for the Congress to give these wonderful Americans the ‘right to try.'”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Policy

IN CASE YOU MISSED IT

  • Biden’s COVID-19 response will make manufacturers busy
  • Mylan must face EpiPen racketeering lawsuit
  • EmblemHealth to provide coverage for Senseonics’ Eversense CGM
  • Eitan Medical lands FDA clearance for infusion pump system upgrade
  • Senseonics announces $50M from stock offering

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS